Literature DB >> 23347185

Direct inhibition of factor VIIa by TFPI and TFPI constructs.

S Peraramelli1, S Thomassen, A Heinzmann, J Rosing, T M Hackeng, R Hartmann, F Scheiflinger, M Dockal.   

Abstract

BACKGROUND: Tissue factor pathway inhibitor (TFPI) is a multi-Kunitz domain protease inhibitor that down-regulates the extrinsic coagulation pathway by inhibiting FXa and FVIIa.
OBJECTIVES: To investigate the role of the three Kunitz domains (KDs) of TFPI in FVIIa inhibition using full-length TFPI (TFPIfl ) and truncated TFPI constructs.
METHODS: Inhibition of FVIIa with/without relipidated tissue factor (TF) or soluble TF (sTF) by TFPIfl /TFPI constructs was quantified with a FVIIa-specific chromogenic substrate. RESULTS AND
CONCLUSIONS: TFPIfl inhibited TF-FVIIa via a monophasic reaction, which is rather slow at low TFPIfl concentrations (t½  ≈ 5 min at 2 nm TFPI) and has a Ki of 4.6 nm. In the presence of sTF and without TF, TFPIfl was a poor FVIIa inhibitor, with Ki values of 122 nm and 1118 nm, respectively. This indicates that phospholipids and TF significantly contribute to FVIIa inhibition by TFPIfl . TFPI constructs without the KD3-c-terminus (TFPI1-150 and KD1-KD2) were 7-10-fold less effective than TFPIfl in inhibiting TF-FVIIa and sTF-FVIIa, indicating that the KD3-C-terminus significantly contributes to direct inhibition of FVIIa by TFPI. Compared with KD1-KD2, KD1 was a poor TF-FVIIa inhibitor (Ki =434 nm), which shows that the KD2 domain of TFPI also contributes to FVIIa inhibition. Protein S stimulated TF-FVIIa inhibition by TFPIfl (Ki =0.7 nm). In the presence of FXa, a tight quaternary TF-FVIIa-TFPI-FXa complex is formed with TFPIfl , TFPI1-150 and KD1-KD2, with Ki values of < 0.15 nm, 0.5 nm and 0.8 nm, respectively, indicating the KD3-C-terminus is not a prerequisite for quaternary complex formation. Phospholipids and the Gla-domain of FXa are required for quaternary complex formation.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347185     DOI: 10.1111/jth.12152

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

Review 1.  A Molecular Revolution in the Treatment of Hemophilia.

Authors:  John S S Butterfield; Kerry M Hege; Roland W Herzog; Radoslaw Kaczmarek
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

Review 2.  Molecular approaches for improved clotting factors for hemophilia.

Authors:  Randal J Kaufman; Jerry S Powell
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

Review 3.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

Review 4.  Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.

Authors:  Maricel G Miguelino; Jerry S Powell
Journal:  Patient Prefer Adherence       Date:  2014-08-08       Impact factor: 2.711

5.  Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.

Authors:  Charles L Percy; Rudolf Hartmann; Rhidian M Jones; Subramaniam Balachandran; Dheeraj Mehta; Michael Dockal; Friedrich Scheiflinger; Valerie B O'Donnell; Judith E Hall; Peter W Collins
Journal:  Blood Coagul Fibrinolysis       Date:  2015-06       Impact factor: 1.276

6.  Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.

Authors:  Stella Thomassen; Tom G Mastenbroek; Frauke Swieringa; Kristien Winckers; Marion A H Feijge; Roy Schrijver; Judith M E M Cosemans; Susan A Maroney; Alan E Mast; Tilman M Hackeng; Johan W M Heemskerk
Journal:  Thromb Haemost       Date:  2018-02-16       Impact factor: 5.249

7.  Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.

Authors:  Björn Dahlbäck; Li Jun Guo; Ruzica Livaja-Koshiar; Sinh Tran
Journal:  Res Pract Thromb Haemost       Date:  2017-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.